PE20051146A1 - Compuestos heterociclicos anticitocina - Google Patents

Compuestos heterociclicos anticitocina

Info

Publication number
PE20051146A1
PE20051146A1 PE2005000254A PE2005000254A PE20051146A1 PE 20051146 A1 PE20051146 A1 PE 20051146A1 PE 2005000254 A PE2005000254 A PE 2005000254A PE 2005000254 A PE2005000254 A PE 2005000254A PE 20051146 A1 PE20051146 A1 PE 20051146A1
Authority
PE
Peru
Prior art keywords
phenyl
compounds
methyl
anticitocin
heterocyclic
Prior art date
Application number
PE2005000254A
Other languages
English (en)
Inventor
Derek A Cogan
Victor Kamhi
Alan D Swinamer
Craig Andrew Miller
Matthew R Netherton
Ming Hong Hao
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of PE20051146A1 publication Critical patent/PE20051146A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

REFERIDA A UN COMPUESTO DE FORMULA I DONDE Ar1 ES UN CARBOCICLO SUSTITUIDO, ENTRE OTROS; D, A Y B SON CADA UNO N, CH; Het ES ANILLO HETEROARILO O HETEROCICLO; R3, R4 Y R6 SON CADA UNO H, HALOGENO, ALQUILO C1-C5, ENTRE OTROS; X ES O, S. SON COMPUESTOS PREFERIDOS: ESTER BENCILICO DEL ACIDO [2-(4-{1-[5-(5-TERC-BUTIL-3-METANSULFONILAMINO-2-METOXI-FENILCARBAMOIL)-2-METIL-FENIL]-1H-1,2,3-TRIAZOL-4-IL}-2-FENIL-2H-PIRAZOL-3-IL)-ETIL]-CARBAMICO; 3-[4-(5-ETIL-1-FENIL-1H-PIRAZOL-4-IL)-IMIDAZOL-1-IL]-N-[3-METANSULFONILAMINO-2-METOXI-5-(1-METIL-CICLOPROPIL)-FENIL]-4-METIL-BENZAMIDA; ENTRE OTROS. DICHOS COMPUESTOS SON INHIBIDORES DE LA PRODUCCION DE CITOCINAS Y SON UTILES EN EL TRATAMIENTO DE AFECCIONES INFLAMATORIAS
PE2005000254A 2004-03-09 2005-03-07 Compuestos heterociclicos anticitocina PE20051146A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55144504P 2004-03-09 2004-03-09

Publications (1)

Publication Number Publication Date
PE20051146A1 true PE20051146A1 (es) 2006-02-02

Family

ID=34962594

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000254A PE20051146A1 (es) 2004-03-09 2005-03-07 Compuestos heterociclicos anticitocina

Country Status (30)

Country Link
US (2) US7214802B2 (es)
EP (2) EP1887003A1 (es)
JP (1) JP4850824B2 (es)
KR (1) KR20060129077A (es)
CN (1) CN1930144A (es)
AR (1) AR048315A1 (es)
AT (1) ATE432273T1 (es)
AU (1) AU2005223738B2 (es)
BR (1) BRPI0508561A (es)
CA (1) CA2557856C (es)
CY (1) CY1109333T1 (es)
DE (1) DE602005014621D1 (es)
DK (1) DK1725544T3 (es)
EA (1) EA011634B1 (es)
EC (1) ECSP066833A (es)
ES (1) ES2327940T3 (es)
HR (1) HRP20090334T1 (es)
IL (1) IL177937A0 (es)
MY (1) MY143000A (es)
NO (1) NO20064120L (es)
NZ (1) NZ550148A (es)
PE (1) PE20051146A1 (es)
PL (1) PL1725544T3 (es)
PT (1) PT1725544E (es)
RS (1) RS50796B (es)
SI (1) SI1725544T1 (es)
TW (1) TW200602313A (es)
UA (1) UA85702C2 (es)
WO (1) WO2005090333A1 (es)
ZA (1) ZA200606177B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009536618A (ja) * 2006-04-18 2009-10-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ４−及び５−イミダゾリル環を含むサイトカイン阻害化合物の製造方法及びその中間体
US20080182837A1 (en) * 2006-07-07 2008-07-31 Steffen Steurer New chemical compounds
PL2090570T3 (pl) 2006-09-05 2012-03-30 Kyowa Hakko Kirin Co Ltd Pochodna imidazolu
WO2009003998A2 (en) * 2007-07-02 2009-01-08 Boehringer Ingelheim International Gmbh Antiproliferative compounds based on 5-membered heterocycles
CL2008001943A1 (es) * 2007-07-02 2009-09-11 Boehringer Ingelheim Int Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes.
US8278340B2 (en) 2007-11-27 2012-10-02 North Carolina State University Inhibition of biofilms in plants with imidazole derivatives
WO2009123753A1 (en) 2008-04-04 2009-10-08 North Carolina State University Inhibition of bacterial biofilms with imidazole-phenyl derivatives
WO2009131654A2 (en) * 2008-04-21 2009-10-29 North Carolina State University Inhibition and dispersion of bacterial biofilms with imidazole-triazole derivatives
US20110212999A1 (en) * 2008-09-02 2011-09-01 Neurosearch A/S Triazole derivatives and their use as nicotinic acetylcholine receptor modulators
TW201014860A (en) 2008-09-08 2010-04-16 Boehringer Ingelheim Int New chemical compounds
JP2012504137A (ja) 2008-09-29 2012-02-16 アボット・ラボラトリーズ インドール誘導体およびインドリン誘導体ならびにそれらの使用方法
US9625475B2 (en) 2008-09-29 2017-04-18 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
KR20110063574A (ko) 2008-09-29 2011-06-10 베링거 인겔하임 인터내셔날 게엠베하 항증식성 화합물
WO2010077603A1 (en) * 2008-12-08 2010-07-08 North Carolina State University Inhibition and dispersion of biofilms in plants with imidazole-triazole derivatives
US8569316B2 (en) 2009-02-17 2013-10-29 Boehringer Ingelheim International Gmbh Pyrimido [5,4-D] pyrimidine derivatives for the inhibition of tyrosine kinases
WO2010144686A1 (en) 2009-06-10 2010-12-16 North Carolina State University Inhibition and dispersion of bacterial biofilms with benzimidazole derivatives
WO2011008312A2 (en) 2009-07-14 2011-01-20 Abbott Laboratories Indole and indoline derivatives and methods of use thereof
US8778959B2 (en) 2009-12-17 2014-07-15 Abbvie Inc. AZA-bridged ring-fused indoles and indolines
WO2011084434A2 (en) 2009-12-17 2011-07-14 Abbott Laboratories Aza-ring fused indole and indoline derivatives
JP5734999B2 (ja) 2009-12-17 2015-06-17 アッヴィ・インコーポレイテッド 神経変性および神経精神医学的障害の治療に有用な架橋アミン環縮合インドールおよびインドリン
US9174949B2 (en) 2010-01-07 2015-11-03 Selexagen Therapeutics, Inc. Hedgehog inhibitors
WO2011085261A1 (en) * 2010-01-08 2011-07-14 Selexagen Therapeutics, Inc. Hedgehog inhibitors
EP2552905B1 (en) 2010-03-26 2016-10-05 Boehringer Ingelheim International GmbH B-Raf kinase inhibitors
US8865703B2 (en) 2010-03-26 2014-10-21 Boehringer Ingelheim International Gmbh Pyridyltriazoles
US8609669B2 (en) 2010-11-16 2013-12-17 Abbvie Inc. Potassium channel modulators
US8466181B2 (en) * 2010-12-10 2013-06-18 Hoffmann-La Roche Inc. 1,2,3-triazole-imidazole compounds
US8710055B2 (en) 2010-12-21 2014-04-29 Boehringer Ingelheim International Gmbh Triazolylphenyl sulfonamides as serine/threonine kinase inhibitors
MY162397A (en) * 2011-01-28 2017-06-15 4Sc Discovery Gmbh Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation
CA2825779C (en) * 2011-01-28 2020-02-25 4Sc Discovery Gmbh Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation
US8889684B2 (en) 2011-02-02 2014-11-18 Boehringer Ingelheim International Gmbh Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
WO2012158399A1 (en) 2011-05-13 2012-11-22 Abbott Laboratories Condensed 2 - carbamoylpyridazinones as potassium channel modulators
JP6054869B2 (ja) 2011-07-29 2016-12-27 武田薬品工業株式会社 複素環化合物
US9447099B2 (en) * 2011-10-04 2016-09-20 Hoffmann-La Roche Inc. Methods for the preparation of 5-[2-[7 (trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo [1,5-A]pyrimidin-3-yl[ethynyl]-2-pyridinamine
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
BR112016010164A2 (pt) * 2013-11-05 2017-08-08 Bayer Cropscience Ag novos compostos para o combate aos ártropodes
WO2017108737A1 (en) 2015-12-23 2017-06-29 Chiesi Farmaceutici S.P.A. 1-(3-tert-butyl-phenyl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro- naphthalen-1-yl)-urea derivatives and their use as p38 mapk inhibitors
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
WO2018102552A1 (en) 2016-11-30 2018-06-07 Case Western Reserve University Combinations of 15-pgdh inhibitors with corcosteroids and/or tnf inhibitors and uses thereof
JP2020514323A (ja) 2017-02-06 2020-05-21 ケース ウエスタン リザーブ ユニバーシティ 短鎖デヒドロゲナーゼ活性を調節する組成物と方法
US10836769B2 (en) 2018-02-26 2020-11-17 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
EP3759095A1 (en) 2018-03-01 2021-01-06 Annapurna Bio Inc. Compounds and compositions for treating conditions associated with apj receptor activity
WO2020007729A1 (en) 2018-07-04 2020-01-09 Boehringer Ingelheim International Gmbh Triazole benzamide derivatives as gpr142 agonists
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
JP2023509260A (ja) 2019-08-14 2023-03-08 インサイト・コーポレイション Ｃｄｋ２阻害剤としてのイミダゾリルピリミジニルアミン化合物
WO2021072232A1 (en) 2019-10-11 2021-04-15 Incyte Corporation Bicyclic amines as cdk2 inhibitors
WO2022188792A1 (zh) * 2021-03-12 2022-09-15 四川科伦博泰生物医药股份有限公司 具有蛋白激酶抑制活性的杂环化合物、包含其的药物组合物及其制备方法和用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4302051A1 (de) 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
FR2732967B1 (fr) 1995-04-11 1997-07-04 Sanofi Sa 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant
ES2239357T3 (es) * 1996-06-10 2005-09-16 MERCK & CO., INC. Imidazoles sustituidos que tienen actividad inhibidora de citoquinas.
JP4385414B2 (ja) * 1997-10-13 2009-12-16 アステラス製薬株式会社 アミド若しくはアミン誘導体
AU751139B2 (en) 1997-10-13 2002-08-08 Astellas Pharma Inc. Amide derivative
AU3387999A (en) * 1998-04-08 1999-10-25 Abbott Laboratories Pyrazole inhibitors of cytokine production
US6506747B1 (en) 1998-06-05 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents
USRE45616E1 (en) 1998-10-13 2015-07-21 Covidien Lp Multi-channel non-invasive tissue oximeter
AU1130700A (en) 1998-10-23 2000-05-15 Dow Agrosciences Llc Insecticidal 1-(substituted pyridyl)-1,2,4-triazoles
US6451820B1 (en) 2000-03-23 2002-09-17 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenly)triazoles and their use as anti-inflammatory agents
US6498423B1 (en) 2001-06-27 2002-12-24 Welch Allyn, Inc. Lamp thermal control by directed air flow
US7297708B2 (en) 2001-09-06 2007-11-20 Bristol-Myers Squibb Company Heteroaromatic substituted cyclopropane as corticotropin releasing hormone ligands
CA2458533C (en) 2001-10-09 2011-01-04 Tularik Inc. Imidazole derivates as anti-inflammatory agents
AU2003209388A1 (en) 2002-01-29 2003-09-02 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
DE602004029242D1 (en) 2003-05-01 2010-11-04 Bristol Myers Squibb Co Pyrazolamidverbindungen

Also Published As

Publication number Publication date
AU2005223738B2 (en) 2011-08-11
NO20064120L (no) 2006-09-26
CY1109333T1 (el) 2014-07-02
BRPI0508561A (pt) 2007-08-14
PL1725544T3 (pl) 2009-10-30
US7214802B2 (en) 2007-05-08
JP4850824B2 (ja) 2012-01-11
EP1725544A1 (en) 2006-11-29
SI1725544T1 (sl) 2009-10-31
EP1887003A1 (en) 2008-02-13
IL177937A0 (en) 2006-12-31
RS50796B (sr) 2010-08-31
WO2005090333A1 (en) 2005-09-29
US20060079519A1 (en) 2006-04-13
NZ550148A (en) 2010-07-30
HRP20090334T1 (en) 2009-07-31
JP2007528395A (ja) 2007-10-11
ECSP066833A (es) 2006-11-24
EP1725544B1 (en) 2009-05-27
EA011634B1 (ru) 2009-04-28
UA85702C2 (ru) 2009-02-25
WO2005090333A8 (en) 2006-08-24
AR048315A1 (es) 2006-04-19
ZA200606177B (en) 2008-12-31
KR20060129077A (ko) 2006-12-14
CA2557856C (en) 2010-06-29
ATE432273T1 (de) 2009-06-15
TW200602313A (en) 2006-01-16
US7514458B2 (en) 2009-04-07
EA200601571A1 (ru) 2007-02-27
MY143000A (en) 2011-02-14
DE602005014621D1 (de) 2009-07-09
ES2327940T3 (es) 2009-11-05
CA2557856A1 (en) 2005-09-29
US20070142371A1 (en) 2007-06-21
CN1930144A (zh) 2007-03-14
DK1725544T3 (da) 2009-07-27
PT1725544E (pt) 2009-07-02
AU2005223738A1 (en) 2005-09-29

Similar Documents

Publication Publication Date Title
PE20051146A1 (es) Compuestos heterociclicos anticitocina
PE20191757A1 (es) Compuestos heterociclicos utiles como inhibidores dobles de atx/ca
PE20141700A1 (es) Compuestos de 2-(2,4,5-anilino sustituido) pirimidina
ATE443701T1 (de) Heterocyclische, ein azol enthaltende sulfonamidinhibitoren der beta-amyloid-produktion
PE20040696A1 (es) Derivados de acido mandelico como inhibidores de la formacion de factores de coagulacion
PE20050691A1 (es) Proceso para preparar carboxamidas 2-aminotiazol-5-aromaticas como inhibidores de la cinasa
PE20091243A1 (es) Compuesto heterociclico fusionado
PE20090617A1 (es) Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20090717A1 (es) Derivados de quinolina como inhibidores de la pi3 quinasa
PE20051155A1 (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
PE20141375A1 (es) Activadores de glucoquinasa
PE20090949A1 (es) Compuesto heterociclico y composicion farmaceutica del mismo
TW200518750A (en) Cornea-conjunctiva disorder treating agent
PE20050132A1 (es) Piperazinas heterociclicas sustituidas
PE20070359A1 (es) Inhibidores de pirimidinilpirazol de aurora quinasas
PE20081059A1 (es) Derivados de pirimidinas como inhibidores de la actividad de la tirosina quinasa de bruton (btk)
PE20070640A1 (es) Compuestos derivados de pirazol-isoquinolina urea como inhibidores de la cinasa p38
PE20080538A1 (es) Derivado heterociclico fusionado y su uso
PE20120834A1 (es) Derivados de furopirimidindiona como moduladores de trpa1
PE20100737A1 (es) Nuevos compuestos
PE20070528A1 (es) Compuestos heterociclicos como ligandos del receptor vaniloide del subtipo 1
PE20060298A1 (es) Derivados de acido carboxilico de bencimidazolona
PE20060727A1 (es) Antranilamidopiridinas como inhibidores de la quinasa receptora del factor de crecimiento vascular endotelial (vegf)

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed